Carol Brosgart, MD
Dr. Carol Brosgart, MD served as the Co-Chair for the National Task Force on Hepatitis B from 2021 to 2024. She also serves as an independent director on the Boards of both public and privately-held biotechnology companies (Galmed, Abivax,Enochian, Intrivo Diagnostics, and Mirum Pharmaceuticals ) and previously served on the Boards of Juvaris (now Bayer) and Tobira (now Allergan, then AbbVie) until they were acquired; as a consultant to global biopharmaceutical companies (currently Dynavax, Hepion, Moderna, and Pardes Biosciences); as a member of the United States Centers for Disease Control (CDC)/Health and Human Services (HHS) Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment, and was the Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC. She has held numerous senior management positions within biotechnology and health care. Dr. Brosgart was the Chief Medical Officer for Alios BioPharma (now Johnson & Johnson), a biotech company developing therapies to treat viral diseases. Dr. Brosgart joined Alios from UCSF Benioff Children’s Hospital & Research Center in Oakland, California, where she served as Senior Vice President and Chief Medical Officer. For eleven years Dr. Brosgart held a number of senior management positions at Gilead Sciences (Vice President, Clinical Research; Vice President, Medical Affairs; and Vice President, Public Health and Policy). While Vice President of Clinical Research at Gilead she was responsible for the clinical development and approval by the FDA and by regulatory authorities worldwide of two antiviral therapies: Viread® for the treatment of HIV, and Hepsera® for the treatment of Chronic Hepatitis B.
She is a member of the Boards of Directors of the Hepatitis B Foundation, the AP Giannini Foundation and the Berkeley Community Scholars. She also serves on the Steering Committee of the HBV Cure Forum of the Forum for Collaborative Research (FCR) at UC Berkeley School of Public Health.
Prior to Gilead, Dr. Brosgart worked for more than 20 years in public health, clinical care, research, and teaching. She was among the first physicians in the United States to recognize and treat patients with HIV/AIDS. Dr. Brosgart was the founding Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California. She led NIH clinical trials as a member of the Community Programs for Clinical Research on AIDS (CPCRA), chaired the CPCRA Scientific Advisory Committee, and contributed to HIV antiretroviral drug development, and to the development of prophylactic and treatment agents for opportunistic and malignant complications of HIV/AIDS.
Dr. Brosgart received her B.S. in Community Medicine from the University of California, Berkeley (UCB), her M.D. from the University of California, San Francisco (UCSF), and her residency training in Pediatrics (UCSF) and Public Health and Preventive Medicine (UCB). She has published extensively in the areas of infectious diseases, focusing on antiviral therapy for HIV, HBV, CMV, and related public health policy. She is an active member of the Infectious Diseases Society of America (IDSA), the HIV Medical Association (HIVMA) and the American Association for the Study of Liver Disease (AASLD). She is Clinical Professor of Medicine, Biostatistics and Epidemiology at UCSF.